The signaling protein Vascular Endothelial Growth Factor (VEGF) is a major contributor to angiogenesis in both health and disease. Since angiogenesis is required for tumour growth and metastasis, drugs targeting VEGF have been increasingly employed in a vast number of cancer therapies. In addition, anti-VEGF therapies have been successfully used for treating ophthalmologic indications and rheumatoid arthritis.
Since the functional activity of VEGF can be measured with the iLite™ VEGF Assay Ready Cells, these can be used for direct comparison of biosimilars and innovator drugs. The iLite™ VEGF Assay Ready Cells is the second in a long line of products for biosimilar comparisons coming this year, adding to the existing iLite™ TNF-α Assay Ready Cells.
For more information, please see the iLite™ product page, and keep an eye out for the next iLite™ launch within inflammation - iLite™ IL-23 Assay Ready Cells!« Back